Masimo (NASDAQ:MASI) Upgraded to “Buy” at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Masimo (NASDAQ:MASI) from a hold rating to a buy rating in a research report report published on Monday morning, MarketBeat Ratings reports. They currently have $170.00 target price on the medical equipment provider’s stock, up from their previous target price of $148.00.

Other equities analysts have also issued reports about the company. Wells Fargo & Company raised Masimo from an equal weight rating to an overweight rating and lifted their price objective for the stock from $117.00 to $160.00 in a research note on Monday, March 25th. StockNews.com raised Masimo from a sell rating to a hold rating in a research note on Friday, March 29th. Piper Sandler boosted their price target on Masimo from $70.00 to $117.00 and gave the company a neutral rating in a research note on Monday, February 26th. Jefferies Financial Group reissued a hold rating and issued a $121.00 price target (up from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. Finally, BTIG Research boosted their price target on Masimo from $145.00 to $166.00 and gave the company a buy rating in a research note on Monday, March 25th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Masimo presently has an average rating of Hold and an average price target of $137.43.

Masimo Stock Performance

Masimo stock opened at $135.92 on Monday. Masimo has a 12-month low of $75.22 and a 12-month high of $198.00. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average price is $135.68 and its two-hundred day moving average price is $114.05. The stock has a market cap of $7.19 billion, a PE ratio of 90.48 and a beta of 0.97.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.43. The company had revenue of $548.90 million for the quarter, compared to analysts’ expectations of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.32 earnings per share. As a group, analysts expect that Masimo will post 3.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

Institutional investors have recently modified their holdings of the company. Riverview Trust Co bought a new stake in Masimo during the first quarter worth $25,000. Massmutual Trust Co. FSB ADV grew its holdings in Masimo by 140.6% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Byrne Asset Management LLC bought a new stake in Masimo during the fourth quarter worth $28,000. DHJJ Financial Advisors Ltd. bought a new stake in Masimo during the third quarter worth $32,000. Finally, NBC Securities Inc. bought a new stake in Masimo during the third quarter worth $34,000. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.